For the fourth consecutive year, Northside Hospital’s Blood & Marrow Transplant (BMT) Program has been reported as having among the best survival outcomes in the country for related and unrelated bone marrow transplants. The data was reported by the National Marrow Donor Program (NMDP), the federally funded organization that facilitates most unrelated bone marrow transplants in the United States. The most recently reported data spans from years 2008 through 2010.
The ranking recognizes the results of Northside’s patient-centered, comprehensive quality management BMT Program, which is overseen by H. Kent Holland, M.D., medical director.
Transplanting healthy marrow may be the best and only hope of a cure for life-threatening diseases such as leukemia, lymphoma and other blood disorders. The BMT Program at Northside serves patients who require bone marrow or stem cell transplants. Patients have access to the full range of available hematopoietic transplants, including those from matched related, matched unrelated and haploidentical donors, and cord blood transplants.
In 2012, 184 transplants were performed at Northside. The one-year survival of patients transplanted at Northside was 78 percent, among the best of any BMT program in the country and exceeding the survival expected by the NMDP.
In 2011, Northside’s BMT Program was asked by the National Cancer Institute (NCI) to join the prestigious group of Core Clinical Centers for the Blood and Marrow Transplant Clinical Trials Network. It is one of only 20 such BMT programs to be awarded this status. The program’s nationally recognized physicians and highly trained professionals, spearhead the work that takes place in the BMT units, laboratory and blood donor center.